But VIVUS (NASDAQ: VVUS ) only reported the number of prescriptions for its obesity drug, Qsymia, that launched last year. While a 68% month-over-month increase is pretty impressive, the actual number of prescriptions -- about 13,000 for the four weeks ending Dec 21. -- is pretty pathetic.
It's understandable why VIVUS might not want to point that out that sales for the quarter will likely be under $5 million. And the sales number could be even worse since VIVUS has been giving away a two-week supply of the drug to encourage patients to get started. VIVUS can't hide the sales number forever. Expect its fourth-quarter earnings call next month.
Back in January the idea of $5 million sales was called a vile slur. Now sales revenue estimate is down to $3.34 million!!!! IN the bigger scheme of things, that ain't much different from 0. Keep that up and we will have $12 million per year. wow, now THAT IS PATHETIC. Not a billion dollar drug I guess. Not $700 million, Not $500 million, NOT even $20 million. The one good thing is that by laying the bar on the ground, even VVUS can step over it.